Mayu Yunokawa - Concepedia

Author

Mayu Yunokawa

Tokyo National Hospital ORCID

Also Known As

M Yunokawa, M. Yunokawa, MAYU YUNOKAWA, Mayu YUNOKAWA, Mayu Yunokawa, Nao Suzuki, Purificacion Estevez, Yunokawa,Mayu

269

Publications

5.9K

Citations

H-Index

Concepts

All Affiliations

Tokyo National Hospital The Cancer Institute Hospital Saitama Medical University National Cancer Center Hospital East Shizuoka Cancer Center

About

Mayu Yunokawa is an author at Tokyo National Hospital specializing in oncology, medicine, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	23	41	3.6K
2	Engineering	4	4	107
3	Health Sciences	4	4	117
4	Biomedical Engineering	1	1	23
5	Biostatistics	1	1	13

Mayu Yunokawa

Publications

5.1K

Citations

H-Index

Page 1

	Year	Citations
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial Éric Pujade-Lauraine, Jonathan A. Ledermann, Frédèric Selle, The Lancet Oncology Brca1/2 MutationMedicineCancer ManagementGynecologyOlaparib Tablets	2017	1.8K
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial Andrés Poveda, Anne Floquet, Jonathan A. Ledermann, The Lancet Oncology	2021	391
<sup>64</sup>Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer Kenji Tamura, Hiroaki Kurihara, Kan Yonemori, Journal of Nuclear Medicine	2013	285
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial Ana Oaknin, Laurence Gladieff, Jerónimo Martínez-García, The Lancet OncologyCervical CancerMetronomic TherapyPathologyRecurrent Cervical Cancer	2023	175
Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer Yuko Tanabe, Kenji Hashimoto, Chikako Shimizu, International Journal of Clinical Oncology Breast OncologyOncologyPharmacologyAdjuvant ChemotherapyBreast Cancer	2011	156
Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer Atsuko Kitano, Makiko Ono, Masayuki Yoshida, ESMO Open	2017	156
64Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients Hiroaki Kurihara, Akinobu Hamada, Masayuki Yoshida, EJNMMI Research	2015	108
Significance of histologic pattern of carcinoma and sarcoma components on survival outcomes of uterine carcinosarcoma Koji Matsuo, Yutaka Takazawa, Malcolm S. Ross, Annals of Oncology Tumoral PathologySarcoma ComponentsMedicineSurgical PathologyGynecology	2016	102
Human mismatch repair gene, MLH1, is transcriptionally repressed by the hypoxia-inducible transcription factors, DEC1 and DEC2 Hideaki Nakamura, Keiji Tanimoto, Keiko Hiyama, Oncogene Genome InstabilityTranscriptional RegulationGeneticsGenomic MechanismMolecular Genetics	2008	94
Efficacy of everolimus, a novel m<scp>TOR</scp> inhibitor, against basal‐like triple‐negative breast cancer cells Mayu Yunokawa, Fumiaki Koizumi, Yuka Kitamura, Cancer Science Breast OncologyChemoprevention StrategyEndocrine-related CancerMtor CascadeMedicine	2012	94

Page 1